NANO — Nanobiotix SA Share News
0.000.00%
Last trade - 00:00- €971.36m
- €967.08m
- €7.84m
Nanobiotix jumps on J&J deal for cancer therapy development
Nanobiotix jumps on J&J deal for cancer therapy development
Brief: Nanobiotix Provides First Quarter 2023 Operational And Financial Update
Nanobiotix soars on final talks for cancer therapy development contract
Nanobiotix surges on final talks for cancer therapy development contract
Brief: Nanobiotix Enters Final Contract Negotiations On NBTXR3 With Major Global Pharmaceutical Company
Brief: Nanobiotix Provides Says FY 2022 Net Loss Attributable To Shareholders Was EUR 1.64 Per Share
NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers pour l’année 2022
NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results
Brief: Nanobiotix To Provide Operational Update And Report Full Year 2022 Financial Results On April 24
NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023
NANOBIOTIX publiera le 24 avril 2023 ses résultats financiers de l’exercice 2022 et fera le point sur ses activités opérationnelles
Brief: Nanobiotix To Postpone Full Year 2022 Financial Results And Conference Call
Brief: Nanobiotix To Provide Operational Update And Report Full Year 2022 Financial Results On March 28, 2023
Brief: Nanobiotix: First Patient Randomized In US In Phase 3 Pivotal Trial Of NBTXR3 In Head And Neck Cancer
Brief: Nanobiotix Announces Termination Of Liquidity Contract And Publishes End Of Contract Statement
Brief: NANOBIOTIX Announces Recommended Phase 2 Dose For NBTXR3 In Pancreatic Cancer
Brief: Nanobiotix Reports Updated Phase 1 Anti-PD-1 Combination Data
Brief: Nanobiotix Provides Third Quarter 2022 Operational And Financial Update